hu.MAP 3.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: huMAP3_10657.1
Confidence: Medium High
Proteins| Genename | Protein Name | Uniprot Annotation Score | Links |
|---|---|---|---|
| AKT1 | RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha) | 5 | UniProt NCBI |
| AKT3 | RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2) | 5 | UniProt NCBI |
| ABHD15 | Protein ABHD15 (Alpha/beta hydrolase domain-containing protein 15) (Abhydrolase domain-containing protein 15) | 4 | UniProt NCBI |
| AKT2 | RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta) | 5 | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| REAC:R-HSA-211163 | 5.61256101945e-09 | 0.75 | AKT1 AKT2 AKT3 | AKT-mediated inactivation of FOXO1A |
| REAC:R-HSA-8941332 | 1.40306823124e-08 | 0.75 | AKT1 AKT2 AKT3 | RUNX2 regulates genes involved in cell migration |
| REAC:R-HSA-198693 | 1.68324973574e-07 | 0.75 | AKT1 AKT2 AKT3 | AKT phosphorylates targets in the nucleus |
| WP:WP5372 | 1.95604750042e-07 | 0.75 | AKT1 AKT2 AKT3 | Involvement of secretase in neurodegenerative diseases |
| REAC:R-HSA-6804759 | 2.31434954766e-07 | 0.75 | AKT1 AKT2 AKT3 | Regulation of TP53 Activity through Association with Co-factors |
| REAC:R-HSA-9614399 | 3.0856409449e-07 | 0.75 | AKT1 AKT2 AKT3 | Regulation of localization of FOXO transcription factors |
| REAC:R-HSA-1358803 | 3.0856409449e-07 | 0.75 | AKT1 AKT2 AKT3 | Downregulation of ERBB2:ERBB3 signaling |
| REAC:R-HSA-210745 | 3.0856409449e-07 | 0.75 | AKT1 AKT2 AKT3 | Regulation of gene expression in beta cells |
| REAC:R-HSA-9755779 | 3.0856409449e-07 | 0.75 | AKT1 AKT2 AKT3 | SARS-CoV-2 targets host intracellular signalling and regulatory pathways |
| WP:WP5294 | 3.38413923581e-07 | 0.75 | AKT1 AKT2 AKT3 | Sildenafil treatment |
| WP:WP4483 | 3.98113575652e-07 | 0.75 | AKT1 AKT2 AKT3 | Relationship between inflammation COX 2 and EGFR |
| REAC:R-HSA-198323 | 4.0111272408e-07 | 0.75 | AKT1 AKT2 AKT3 | AKT phosphorylates targets in the cytosol |
| WP:WP26 | 6.18377614493e-07 | 0.75 | AKT1 AKT2 AKT3 | S1P receptor signal transduction |
| REAC:R-HSA-111447 | 6.38068337719e-07 | 0.75 | AKT1 AKT2 AKT3 | Activation of BAD and translocation to mitochondria |
| WP:WP5385 | 7.06680962276e-07 | 0.75 | AKT1 AKT2 AKT3 | Growth factors and hormones in Beta cell proliferation |
| WP:WP3965 | 9.07698459722e-07 | 0.75 | AKT1 AKT2 AKT3 | Lipid metabolism pathway |
| WP:WP4561 | 9.07698459722e-07 | 0.75 | AKT1 AKT2 AKT3 | Cell migration and invasion through p75NTR |
| WP:WP4481 | 1.14358251355e-06 | 0.75 | AKT1 AKT2 AKT3 | Resistin as a regulator of inflammation |
| REAC:R-HSA-389513 | 1.14413965008e-06 | 0.75 | AKT1 AKT2 AKT3 | CTLA4 inhibitory signaling |
| WP:WP5358 | 1.27546878771e-06 | 0.75 | AKT1 AKT2 AKT3 | JAK STAT signaling in the regulation of Beta cells |
| REAC:R-HSA-9634638 | 1.59826617962e-06 | 0.75 | AKT1 AKT2 AKT3 | Estrogen-dependent nuclear events downstream of ESR-membrane signaling |
| REAC:R-HSA-389357 | 1.59826617962e-06 | 0.75 | AKT1 AKT2 AKT3 | CD28 dependent PI3K/Akt signaling |
| REAC:R-HSA-392451 | 1.86454808481e-06 | 0.75 | AKT1 AKT2 AKT3 | G beta:gamma signalling through PI3Kgamma |
| WP:WP4564 | 2.08824407225e-06 | 0.75 | AKT1 AKT2 AKT3 | Neural crest cell migration during development |
| KEGG:04973 | 2.24311561366e-06 | 0.75 | AKT1 AKT2 AKT3 | Carbohydrate digestion and absorption |
| WP:WP4565 | 2.49139866959e-06 | 0.75 | AKT1 AKT2 AKT3 | Neural crest cell migration in cancer |
| REAC:R-HSA-5218920 | 2.8370403595e-06 | 0.75 | AKT1 AKT2 AKT3 | VEGFR2 mediated vascular permeability |
| REAC:R-HSA-8863795 | 2.8370403595e-06 | 0.75 | AKT1 AKT2 AKT3 | Downregulation of ERBB2 signaling |
| WP:WP5373 | 3.18842863723e-06 | 0.75 | AKT1 AKT2 AKT3 | Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy |
| REAC:R-HSA-5674400 | 3.2237438451e-06 | 0.75 | AKT1 AKT2 AKT3 | Constitutive Signaling by AKT1 E17K in Cancer |
| REAC:R-HSA-186712 | 3.2237438451e-06 | 0.75 | AKT1 AKT2 AKT3 | Regulation of beta-cell development |
| WP:WP4566 | 3.71869501007e-06 | 0.75 | AKT1 AKT2 AKT3 | Translation inhibitors in chronically activated PDGFRA cells |
| REAC:R-HSA-397795 | 4.0993398561e-06 | 0.75 | AKT1 AKT2 AKT3 | G-protein beta:gamma signalling |
| KEGG:04923 | 4.22779284136e-06 | 0.75 | AKT1 AKT2 AKT3 | Regulation of lipolysis in adipocytes |
| WP:WP4539 | 4.61939945286e-06 | 0.75 | AKT1 AKT2 AKT3 | Synaptic signaling pathways associated with autism spectrum disorder |
| KEGG:04929 | 4.86072516083e-06 | 0.75 | AKT1 AKT2 AKT3 | GnRH secretion |
| REAC:R-HSA-389356 | 5.12049513312e-06 | 0.75 | AKT1 AKT2 AKT3 | CD28 co-stimulation |
| WP:WP5144 | 5.65478736993e-06 | 0.75 | AKT1 AKT2 AKT3 | NRP1 triggered signaling pathways in pancreatic cancer |
| REAC:R-HSA-6804758 | 5.68914662089e-06 | 0.75 | AKT1 AKT2 AKT3 | Regulation of TP53 Activity through Acetylation |
| REAC:R-HSA-114452 | 5.68914662089e-06 | 0.75 | AKT1 AKT2 AKT3 | Activation of BH3-only proteins |
| REAC:R-HSA-9607240 | 6.94957302308e-06 | 0.75 | AKT1 AKT2 AKT3 | FLT3 Signaling |
| KEGG:04370 | 7.13131503768e-06 | 0.75 | AKT1 AKT2 AKT3 | VEGF signaling pathway |
| KEGG:05213 | 7.56753675899e-06 | 0.75 | AKT1 AKT2 AKT3 | Endometrial cancer |
| KEGG:04664 | 8.02117619688e-06 | 0.75 | AKT1 AKT2 AKT3 | Fc epsilon RI signaling pathway |
| KEGG:04213 | 8.49257304271e-06 | 0.75 | AKT1 AKT2 AKT3 | Longevity regulating pathway - multiple species |
| REAC:R-HSA-6804757 | 9.16893973468e-06 | 0.75 | AKT1 AKT2 AKT3 | Regulation of TP53 Degradation |
| REAC:R-HSA-6806003 | 1.00019654619e-05 | 0.75 | AKT1 AKT2 AKT3 | Regulation of TP53 Expression and Degradation |
| WP:WP4205 | 1.01988257731e-05 | 0.75 | AKT1 AKT2 AKT3 | MET in type 1 papillary renal cell carcinoma |
| WP:WP4155 | 1.01988257731e-05 | 0.75 | AKT1 AKT2 AKT3 | Endometrial cancer |
| KEGG:05221 | 1.11278026553e-05 | 0.75 | AKT1 AKT2 AKT3 | Acute myeloid leukemia |
| WP:WP5293 | 1.13301263399e-05 | 0.75 | AKT1 AKT2 AKT3 | Acute myeloid leukemia |
| WP:WP4685 | 1.19258348573e-05 | 0.75 | AKT1 AKT2 AKT3 | Melanoma |
| KEGG:05218 | 1.2943754201e-05 | 0.75 | AKT1 AKT2 AKT3 | Melanoma |
| KEGG:04917 | 1.2943754201e-05 | 0.75 | AKT1 AKT2 AKT3 | Prolactin signaling pathway |
| KEGG:04920 | 1.35902422006e-05 | 0.75 | AKT1 AKT2 AKT3 | Adipocytokine signaling pathway |
| KEGG:05211 | 1.49470084516e-05 | 0.75 | AKT1 AKT2 AKT3 | Renal cell carcinoma |
| KEGG:05230 | 1.63910874597e-05 | 0.75 | AKT1 AKT2 AKT3 | Central carbon metabolism in cancer |
| WP:WP4216 | 1.66891072317e-05 | 0.75 | AKT1 AKT2 AKT3 | Chromosomal and microsatellite instability in colorectal cancer |
| WP:WP4255 | 1.66891072317e-05 | 0.75 | AKT1 AKT2 AKT3 | Non small cell lung cancer |
| KEGG:05223 | 1.71467161414e-05 | 0.75 | AKT1 AKT2 AKT3 | Non-small cell lung cancer |
| KEGG:05214 | 1.71467161414e-05 | 0.75 | AKT1 AKT2 AKT3 | Glioma |
| KEGG:04662 | 1.71467161414e-05 | 0.75 | AKT1 AKT2 AKT3 | B cell receptor signaling pathway |
| REAC:R-HSA-1227986 | 1.72814889866e-05 | 0.75 | AKT1 AKT2 AKT3 | Signaling by ERBB2 |
| KEGG:01524 | 1.8726845031e-05 | 0.75 | AKT1 AKT2 AKT3 | Platinum drug resistance |
| WP:WP4674 | 1.90673331224e-05 | 0.75 | AKT1 AKT2 AKT3 | Head and neck squamous cell carcinoma |
| KEGG:05212 | 2.04010593609e-05 | 0.75 | AKT1 AKT2 AKT3 | Pancreatic cancer |
| KEGG:01521 | 2.21720662311e-05 | 0.75 | AKT1 AKT2 AKT3 | EGFR tyrosine kinase inhibitor resistance |
| KEGG:05220 | 2.21720662311e-05 | 0.75 | AKT1 AKT2 AKT3 | Chronic myeloid leukemia |
| KEGG:04012 | 2.40425716137e-05 | 0.75 | AKT1 AKT2 AKT3 | ErbB signaling pathway |
| WP:WP2261 | 2.54708175834e-05 | 0.75 | AKT1 AKT2 AKT3 | Glioblastoma signaling pathways |
| KEGG:05210 | 2.60152803533e-05 | 0.75 | AKT1 AKT2 AKT3 | Colorectal cancer |
| WP:WP4806 | 2.75324569545e-05 | 0.75 | AKT1 AKT2 AKT3 | EGFR tyrosine kinase inhibitor resistance |
| KEGG:05235 | 2.80928961665e-05 | 0.75 | AKT1 AKT2 AKT3 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
| KEGG:04211 | 2.91718888289e-05 | 0.75 | AKT1 AKT2 AKT3 | Longevity regulating pathway |
| WP:WP4263 | 2.97022868077e-05 | 0.75 | AKT1 AKT2 AKT3 | Pancreatic adenocarcinoma pathway |
| WP:WP673 | 2.97022868077e-05 | 0.75 | AKT1 AKT2 AKT3 | ErbB signaling pathway |
| KEGG:04914 | 3.02781216426e-05 | 0.75 | AKT1 AKT2 AKT3 | Progesterone-mediated oocyte maturation |
| KEGG:01522 | 3.02781216426e-05 | 0.75 | AKT1 AKT2 AKT3 | Endocrine resistance |
| REAC:R-HSA-109606 | 3.0932996971e-05 | 0.75 | AKT1 AKT2 AKT3 | Intrinsic Pathway for Apoptosis |
| KEGG:05231 | 3.1411932255e-05 | 0.75 | AKT1 AKT2 AKT3 | Choline metabolism in cancer |
| WP:WP75 | 3.1983058296e-05 | 0.75 | AKT1 AKT2 AKT3 | Toll like receptor signaling pathway |
| WP:WP185 | 3.31659065747e-05 | 0.75 | AKT1 AKT2 AKT3 | Integrin mediated cell adhesion |
| KEGG:04625 | 3.37636371132e-05 | 0.75 | AKT1 AKT2 AKT3 | C-type lectin receptor signaling pathway |
| KEGG:05222 | 3.49822063014e-05 | 0.75 | AKT1 AKT2 AKT3 | Small cell lung cancer |
| KEGG:04620 | 3.62297031734e-05 | 0.75 | AKT1 AKT2 AKT3 | Toll-like receptor signaling pathway |
| KEGG:04933 | 3.62297031734e-05 | 0.75 | AKT1 AKT2 AKT3 | AGE-RAGE signaling pathway in diabetic complications |
| KEGG:05142 | 3.7506465024e-05 | 0.75 | AKT1 AKT2 AKT3 | Chagas disease |
| WP:WP1559 | 3.82933516227e-05 | 0.5 | AKT1 AKT2 | Transcription factors regulate miRNAs related to cardiac hypertrophy |
| KEGG:04725 | 3.88128290779e-05 | 0.75 | AKT1 AKT2 AKT3 | Cholinergic synapse |
| WP:WP4658 | 3.95185168793e-05 | 0.75 | AKT1 AKT2 AKT3 | Small cell lung cancer |
| KEGG:05215 | 4.01491324891e-05 | 0.75 | AKT1 AKT2 AKT3 | Prostate cancer |
| KEGG:04666 | 4.01491324891e-05 | 0.75 | AKT1 AKT2 AKT3 | Fc gamma R-mediated phagocytosis |
| REAC:R-HSA-388841 | 4.09441910601e-05 | 0.75 | AKT1 AKT2 AKT3 | Costimulation by the CD28 family |
| KEGG:05145 | 4.15157123412e-05 | 0.75 | AKT1 AKT2 AKT3 | Toxoplasmosis |
| KEGG:04915 | 4.29129056473e-05 | 0.75 | AKT1 AKT2 AKT3 | Estrogen signaling pathway |
| KEGG:04922 | 4.29129056473e-05 | 0.75 | AKT1 AKT2 AKT3 | Glucagon signaling pathway |
| KEGG:04668 | 4.7291535364e-05 | 0.75 | AKT1 AKT2 AKT3 | TNF signaling pathway |
| REAC:R-HSA-9614085 | 4.78774392083e-05 | 0.75 | AKT1 AKT2 AKT3 | FOXO-mediated transcription |
| KEGG:04611 | 5.19578118732e-05 | 0.75 | AKT1 AKT2 AKT3 | Platelet activation |
| KEGG:04931 | 5.19578118732e-05 | 0.75 | AKT1 AKT2 AKT3 | Insulin resistance |
| REAC:R-HSA-9009391 | 5.2908776296e-05 | 0.75 | AKT1 AKT2 AKT3 | Extra-nuclear estrogen signaling |
| KEGG:04066 | 5.35787298046e-05 | 0.75 | AKT1 AKT2 AKT3 | HIF-1 signaling pathway |
| KEGG:04722 | 5.52329547577e-05 | 0.75 | AKT1 AKT2 AKT3 | Neurotrophin signaling pathway |
| KEGG:04935 | 5.52329547577e-05 | 0.75 | AKT1 AKT2 AKT3 | Growth hormone synthesis, secretion and action |
| WP:WP3931 | 5.62371902988e-05 | 0.75 | AKT1 AKT2 AKT3 | Embryonic stem cell pluripotency pathways |
| WP:WP710 | 5.79557471679e-05 | 0.75 | AKT1 AKT2 AKT3 | DNA damage response only ATM dependent |
| KEGG:04071 | 6.03988351827e-05 | 0.75 | AKT1 AKT2 AKT3 | Sphingolipid signaling pathway |
| KEGG:04660 | 6.03988351827e-05 | 0.75 | AKT1 AKT2 AKT3 | T cell receptor signaling pathway |
| KEGG:04919 | 6.40154556396e-05 | 0.75 | AKT1 AKT2 AKT3 | Thyroid hormone signaling pathway |
| KEGG:04926 | 6.9706157818e-05 | 0.75 | AKT1 AKT2 AKT3 | Relaxin signaling pathway |
| REAC:R-HSA-8948751 | 7.00887667092e-05 | 0.75 | AKT1 AKT2 AKT3 | Regulation of PTEN stability and activity |
| KEGG:04728 | 7.16752745545e-05 | 0.75 | AKT1 AKT2 AKT3 | Dopaminergic synapse |
| KEGG:04371 | 7.57238466156e-05 | 0.75 | AKT1 AKT2 AKT3 | Apelin signaling pathway |
| KEGG:04068 | 7.99217742683e-05 | 0.75 | AKT1 AKT2 AKT3 | FoxO signaling pathway |
| KEGG:04152 | 7.99217742683e-05 | 0.75 | AKT1 AKT2 AKT3 | AMPK signaling pathway |
| KEGG:05135 | 8.42717414951e-05 | 0.75 | AKT1 AKT2 AKT3 | Yersinia infection |
| KEGG:04380 | 8.42717414951e-05 | 0.75 | AKT1 AKT2 AKT3 | Osteoclast differentiation |
| KEGG:04072 | 8.65045783849e-05 | 0.75 | AKT1 AKT2 AKT3 | Phospholipase D signaling pathway |
| KEGG:05418 | 8.87764311506e-05 | 0.75 | AKT1 AKT2 AKT3 | Fluid shear stress and atherosclerosis |
| KEGG:04261 | 9.34385249616e-05 | 0.75 | AKT1 AKT2 AKT3 | Adrenergic signaling in cardiomyocytes |
| KEGG:04550 | 9.58294361569e-05 | 0.75 | AKT1 AKT2 AKT3 | Signaling pathways regulating pluripotency of stem cells |
| KEGG:04210 | 9.58294361569e-05 | 0.75 | AKT1 AKT2 AKT3 | Apoptosis |
| REAC:R-HSA-2219528 | 9.82762051365e-05 | 0.75 | AKT1 AKT2 AKT3 | PI3K/AKT Signaling in Cancer |
| WP:WP3929 | 0.000100047261774 | 0.75 | AKT1 AKT2 AKT3 | Chemokine signaling pathway |
| KEGG:05162 | 0.000105799991328 | 0.75 | AKT1 AKT2 AKT3 | Measles |
| KEGG:04936 | 0.000105799991328 | 0.75 | AKT1 AKT2 AKT3 | Alcoholic liver disease |
| KEGG:04022 | 0.000108396031683 | 0.75 | AKT1 AKT2 AKT3 | cGMP-PKG signaling pathway |
| KEGG:05017 | 0.000108396031683 | 0.75 | AKT1 AKT2 AKT3 | Spinocerebellar ataxia |
| REAC:R-HSA-5628897 | 0.000110531761496 | 0.75 | AKT1 AKT2 AKT3 | TP53 Regulates Metabolic Genes |
| KEGG:04910 | 0.000111034102003 | 0.75 | AKT1 AKT2 AKT3 | Insulin signaling pathway |
| KEGG:05224 | 0.000113714536833 | 0.75 | AKT1 AKT2 AKT3 | Breast cancer |
| REAC:R-HSA-8876198 | 0.000119242757257 | 0.75 | AKT1 AKT2 AKT3 | RAB GEFs exchange GTP for GDP on RABs |
| REAC:R-HSA-199418 | 0.000119242757257 | 0.75 | AKT1 AKT2 AKT3 | Negative regulation of the PI3K/AKT network |
| REAC:R-HSA-69202 | 0.000123764584817 | 0.75 | AKT1 AKT2 AKT3 | Cyclin E associated events during G1/S transition |
| KEGG:04630 | 0.000124866609719 | 0.75 | AKT1 AKT2 AKT3 | JAK-STAT signaling pathway |
| KEGG:05160 | 0.000124866609719 | 0.75 | AKT1 AKT2 AKT3 | Hepatitis C |
| KEGG:05226 | 0.000124866609719 | 0.75 | AKT1 AKT2 AKT3 | Gastric cancer |
| WP:WP4239 | 0.000130086862517 | 0.75 | AKT1 AKT2 AKT3 | Epithelial to mesenchymal transition in colorectal cancer |
| WP:WP4262 | 0.000133081990362 | 0.75 | AKT1 AKT2 AKT3 | Breast cancer pathway |
| REAC:R-HSA-69656 | 0.000133147800117 | 0.75 | AKT1 AKT2 AKT3 | Cyclin A:Cdk2-associated events at S phase entry |
| WP:WP4396 | 0.000145521073611 | 0.75 | AKT1 AKT2 AKT3 | Nonalcoholic fatty liver disease |
| WP:WP4666 | 0.000145521073611 | 0.75 | AKT1 AKT2 AKT3 | Hepatitis B infection |
| REAC:R-HSA-4420097 | 0.000148092217351 | 0.75 | AKT1 AKT2 AKT3 | VEGFA-VEGFR2 Pathway |
| KEGG:04932 | 0.000149305865271 | 0.75 | AKT1 AKT2 AKT3 | Non-alcoholic fatty liver disease |
| KEGG:04062 | 0.000149305865271 | 0.75 | AKT1 AKT2 AKT3 | Chemokine signaling pathway |
| KEGG:04218 | 0.000152567450385 | 0.75 | AKT1 AKT2 AKT3 | Cellular senescence |
| KEGG:05164 | 0.000166087532962 | 0.75 | AKT1 AKT2 AKT3 | Influenza A |
| KEGG:05152 | 0.000173136486645 | 0.75 | AKT1 AKT2 AKT3 | Tuberculosis |
| WP:WP4223 | 0.000179947709834 | 0.75 | AKT1 AKT2 AKT3 | Ras signaling |
| KEGG:04150 | 0.000180381602802 | 0.75 | AKT1 AKT2 AKT3 | mTOR signaling pathway |
| KEGG:05161 | 0.000180381602802 | 0.75 | AKT1 AKT2 AKT3 | Hepatitis B |
| KEGG:04613 | 0.000184078554429 | 0.75 | AKT1 AKT2 AKT3 | Neutrophil extracellular trap formation |
| REAC:R-HSA-194138 | 0.000193308465722 | 0.75 | AKT1 AKT2 AKT3 | Signaling by VEGF |
| KEGG:04140 | 0.000211376960202 | 0.75 | AKT1 AKT2 AKT3 | Autophagy - animal |
| KEGG:04024 | 0.000219642829889 | 0.75 | AKT1 AKT2 AKT3 | cAMP signaling pathway |
| KEGG:05225 | 0.000223855147755 | 0.75 | AKT1 AKT2 AKT3 | Hepatocellular carcinoma |
| KEGG:05207 | 0.000241241390361 | 0.75 | AKT1 AKT2 AKT3 | Chemical carcinogenesis - receptor activation |
| REAC:R-HSA-8878166 | 0.000246885749652 | 0.75 | AKT1 AKT2 AKT3 | Transcriptional regulation by RUNX2 |
| REAC:R-HSA-9755511 | 0.00025420587395 | 0.75 | AKT1 AKT2 AKT3 | KEAP1-NFE2L2 pathway |
| KEGG:04015 | 0.000254854188265 | 0.75 | AKT1 AKT2 AKT3 | Rap1 signaling pathway |
| KEGG:05167 | 0.000264207276718 | 0.75 | AKT1 AKT2 AKT3 | Kaposi sarcoma-associated herpesvirus infection |
| REAC:R-HSA-9007101 | 0.000284930280132 | 0.75 | AKT1 AKT2 AKT3 | Rab regulation of trafficking |
| KEGG:04510 | 0.000288581954849 | 0.75 | AKT1 AKT2 AKT3 | Focal adhesion |
| WP:WP306 | 0.000293828899482 | 0.75 | AKT1 AKT2 AKT3 | Focal adhesion |
| KEGG:05169 | 0.000325152133201 | 0.75 | AKT1 AKT2 AKT3 | Epstein-Barr virus infection |
| KEGG:05417 | 0.000325152133201 | 0.75 | AKT1 AKT2 AKT3 | Lipid and atherosclerosis |
| KEGG:05415 | 0.000336138721134 | 0.75 | AKT1 AKT2 AKT3 | Diabetic cardiomyopathy |
| KEGG:05205 | 0.000336138721134 | 0.75 | AKT1 AKT2 AKT3 | Proteoglycans in cancer |
| KEGG:04014 | 0.000347369255466 | 0.75 | AKT1 AKT2 AKT3 | Ras signaling pathway |
| KEGG:05163 | 0.000394783718861 | 0.75 | AKT1 AKT2 AKT3 | Human cytomegalovirus infection |
| KEGG:05170 | 0.00040099636109 | 0.75 | AKT1 AKT2 AKT3 | Human immunodeficiency virus 1 infection |
| KEGG:04810 | 0.000413615830979 | 0.75 | AKT1 AKT2 AKT3 | Regulation of actin cytoskeleton |
| KEGG:05166 | 0.000433035444638 | 0.75 | AKT1 AKT2 AKT3 | Human T-cell leukemia virus 1 infection |
| KEGG:05208 | 0.000459857531952 | 0.75 | AKT1 AKT2 AKT3 | Chemical carcinogenesis - reactive oxygen species |
| WP:WP382 | 0.000461288756706 | 0.75 | AKT1 AKT2 AKT3 | MAPK signaling pathway |
| REAC:R-HSA-69206 | 0.000498740793897 | 0.75 | AKT1 AKT2 AKT3 | G1/S Transition |
| REAC:R-HSA-6807070 | 0.000558868800628 | 0.75 | AKT1 AKT2 AKT3 | PTEN Regulation |
| KEGG:05132 | 0.000627272119201 | 0.75 | AKT1 AKT2 AKT3 | Salmonella infection |
| KEGG:05131 | 0.000652828786911 | 0.75 | AKT1 AKT2 AKT3 | Shigellosis |
| WP:WP2059 | 0.000700475429532 | 0.75 | AKT1 AKT2 AKT3 | Alzheimer 39 s disease and miRNA effects |
| WP:WP5124 | 0.000700475429532 | 0.75 | AKT1 AKT2 AKT3 | Alzheimer 39 s disease |
| REAC:R-HSA-453279 | 0.000722417813202 | 0.75 | AKT1 AKT2 AKT3 | Mitotic G1 phase and G1/S transition |
| REAC:R-HSA-5633007 | 0.000799005459147 | 0.75 | AKT1 AKT2 AKT3 | Regulation of TP53 Activity |
| KEGG:04010 | 0.000800866642312 | 0.75 | AKT1 AKT2 AKT3 | MAPK signaling pathway |
| WP:WP3932 | 0.000866797679386 | 0.75 | AKT1 AKT2 AKT3 | Focal adhesion PI3K Akt mTOR signaling pathway |
| REAC:R-HSA-69242 | 0.000915028341188 | 0.75 | AKT1 AKT2 AKT3 | S Phase |
| WP:WP5420 | 0.00101030857977 | 0.75 | AKT1 AKT2 AKT3 | ADHD and autism ASD linked metabolic pathways and SNP |
| REAC:R-HSA-109581 | 0.00104173974765 | 0.75 | AKT1 AKT2 AKT3 | Apoptosis |
| WP:WP4172 | 0.001130836436 | 0.75 | AKT1 AKT2 AKT3 | PI3K Akt signaling pathway |
| WP:WP4871 | 0.00126323103486 | 0.5 | AKT1 AKT2 | Kisspeptin kisspeptin receptor system in the ovary |
| KEGG:04151 | 0.00130520637951 | 0.75 | AKT1 AKT2 AKT3 | PI3K-Akt signaling pathway |
| REAC:R-HSA-9711123 | 0.00139682528939 | 0.75 | AKT1 AKT2 AKT3 | Cellular response to chemical stress |
| KEGG:05165 | 0.00141764261548 | 0.75 | AKT1 AKT2 AKT3 | Human papillomavirus infection |
| REAC:R-HSA-8939211 | 0.0014432337528 | 0.75 | AKT1 AKT2 AKT3 | ESR-mediated signaling |
| REAC:R-HSA-9705683 | 0.00151474987795 | 0.75 | AKT1 AKT2 AKT3 | SARS-CoV-2-host interactions |
| WP:WP2036 | 0.00160392090455 | 0.5 | AKT1 AKT2 | TNF related weak inducer of apoptosis TWEAK signaling pathway |
| REAC:R-HSA-5357801 | 0.00166476808943 | 0.75 | AKT1 AKT2 AKT3 | Programmed Cell Death |
| KEGG:05010 | 0.00219039316089 | 0.75 | AKT1 AKT2 AKT3 | Alzheimer disease |
| WP:WP2795 | 0.002190823719 | 0.5 | AKT1 AKT2 | Cardiac hypertrophic response |
| WP:WP2018 | 0.00263260594128 | 0.5 | AKT1 AKT2 | RANKL RANK signaling pathway |
| KEGG:05168 | 0.00275266829871 | 0.75 | AKT1 AKT2 AKT3 | Herpes simplex virus 1 infection |
| REAC:R-HSA-1257604 | 0.00277575065107 | 0.75 | AKT1 AKT2 AKT3 | PIP3 activates AKT signaling |
| WP:WP5087 | 0.0029183957539 | 0.75 | AKT1 AKT2 AKT3 | Pleural mesothelioma |
| HP:0001528 | 0.00303997345979 | 0.5 | AKT1 AKT2 | Hemihypertrophy |
| REAC:R-HSA-9006931 | 0.00343792850162 | 0.75 | AKT1 AKT2 AKT3 | Signaling by Nuclear Receptors |
| REAC:R-HSA-9006925 | 0.00424519576246 | 0.75 | AKT1 AKT2 AKT3 | Intracellular signaling by second messengers |
| REAC:R-HSA-9694516 | 0.00464100691605 | 0.75 | AKT1 AKT2 AKT3 | SARS-CoV-2 Infection |
| WP:WP1403 | 0.00464837292584 | 0.5 | AKT1 AKT2 | AMP activated protein kinase signaling |
| KEGG:05200 | 0.0049271234807 | 0.75 | AKT1 AKT2 AKT3 | Pathways in cancer |
| WP:WP1544 | 0.00595470242757 | 0.5 | AKT1 AKT2 | MicroRNAs in cardiomyocyte hypertrophy |
| REAC:R-HSA-3769402 | 0.00643909852192 | 0.5 | AKT1 AKT2 | Deactivation of the beta-catenin transactivating complex |
| HP:0012246 | 0.00771122114953 | 0.5 | AKT1 AKT3 | Oculomotor nerve palsy |
| REAC:R-HSA-165159 | 0.00837722051003 | 0.5 | AKT1 AKT2 | MTOR signalling |
| GO:0010748 | 0.00842684400117 | 0.5 | AKT1 AKT2 | negative regulation of long-chain fatty acid import across plasma membrane |
| GO:0140213 | 0.00842684400117 | 0.5 | AKT1 AKT2 | negative regulation of long-chain fatty acid import into cell |
| REAC:R-HSA-3700989 | 0.00879681508035 | 0.75 | AKT1 AKT2 AKT3 | Transcriptional Regulation by TP53 |
| REAC:R-HSA-388396 | 0.0112517828268 | 0.75 | AKT1 AKT2 AKT3 | GPCR downstream signalling |
| REAC:R-HSA-5663202 | 0.0116223099825 | 0.75 | AKT1 AKT2 AKT3 | Diseases of signal transduction by growth factor receptors and second messengers |
| REAC:R-HSA-9679506 | 0.0120967178818 | 0.75 | AKT1 AKT2 AKT3 | SARS-CoV Infections |
| WP:WP3915 | 0.0162815495406 | 0.5 | AKT1 AKT2 | Angiopoietin like protein 8 regulatory pathway |
| REAC:R-HSA-372790 | 0.0165968987372 | 0.75 | AKT1 AKT2 AKT3 | Signaling by GPCR |
| GO:0010746 | 0.0168521501606 | 0.5 | AKT1 AKT2 | regulation of long-chain fatty acid import across plasma membrane |
| REAC:R-HSA-9006934 | 0.0183118305735 | 0.75 | AKT1 AKT2 AKT3 | Signaling by Receptor Tyrosine Kinases |
| REAC:R-HSA-1445148 | 0.0239057396727 | 0.5 | AKT1 AKT2 | Translocation of SLC2A4 (GLUT4) to the plasma membrane |
| WP:WP2366 | 0.0248784837172 | 0.25 | AKT1 | Butyrate induced histone acetylation |
| CORUM:7266 | 0.0249718442456 | 0.25 | AKT1 | AKT1-NQO2 complex |
| WP:WP481 | 0.0255965717397 | 0.5 | AKT1 AKT2 | Insulin signaling |
| GO:0010918 | 0.0280843539964 | 0.5 | AKT1 AKT2 | positive regulation of mitochondrial membrane potential |
| HP:0012377 | 0.03008608933 | 0.5 | AKT1 AKT3 | Hemianopia |
| REAC:R-HSA-69278 | 0.0329329593357 | 0.75 | AKT1 AKT2 AKT3 | Cell Cycle, Mitotic |
| GO:2000192 | 0.042122686785 | 0.5 | AKT1 AKT2 | negative regulation of fatty acid transport |
| GO:0140212 | 0.042122686785 | 0.5 | AKT1 AKT2 | regulation of long-chain fatty acid import into cell |
| GO:0060644 | 0.042122686785 | 0.5 | AKT1 AKT2 | mammary gland epithelial cell differentiation |
| REAC:R-HSA-199991 | 0.0424877030349 | 0.75 | AKT1 AKT2 AKT3 | Membrane Trafficking |
| CORUM:2156 | 0.049938562206 | 0.25 | AKT1 | YBX1-AKT1 complex |
| CORUM:2159 | 0.049938562206 | 0.25 | AKT1 | AR-AKT-APPL complex |
| CORUM:3138 | 0.049938562206 | 0.25 | AKT2 | POSH-AKT2 complex |
| CORUM:3847 | 0.049938562206 | 0.25 | AKT1 | TCL1(trimer)-AKT1 complex |
| CORUM:3848 | 0.049938562206 | 0.25 | AKT2 | TCL1(trimer)-AKT2 complex |
| CORUM:5718 | 0.049938562206 | 0.25 | AKT1 | NOS3-HSP90-AKT complex, VEGF induced |
| REAC:R-HSA-5653656 | 0.0499402458571 | 0.75 | AKT1 AKT2 AKT3 | Vesicle-mediated transport |
Edges
| Protein 1 | Protein 2 | Score | ProteomeHD | Evidence |
|---|---|---|---|---|
| AKT1 | AKT2 | 0.999 | 0.376 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM youn_WMM bioplex3_HCT116 |
| AKT1 | AKT3 | 0.999 | 0.278 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 |
| ABHD15 | AKT3 | 0.982 | 0.198 | bioplex3_WMM bioplex3_HCT116 WMM_only |
| AKT1 | ABHD15 | 0.982 | 0.195829959514 | bioplex3_WMM bioplex3_HCT116 WMM_only |
| AKT3 | AKT2 | 0.897 | 0.17 | bioplex_WMM bioplex3_WMM WMM_only |
| ABHD15 | AKT2 | 0.401 | 0.13 | bioplex3_WMM WMM_only |
Related Complexes
| Genename | Complexes |
|---|---|
| AKT1 | huMAP3_02055.1 huMAP3_10657.1 |
| AKT3 | huMAP3_02055.1 huMAP3_10657.1 huMAP3_13837.1 huMAP3_14477.1 |
| ABHD15 | huMAP3_02055.1 huMAP3_10657.1 huMAP3_13774.1 huMAP3_14723.1 |
| AKT2 | huMAP3_04364.1 huMAP3_10657.1 huMAP3_13151.1 |